An Open Label Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2013
At a glance
- Drugs Afatinib (Primary)
- Indications Biliary cancer; Bladder cancer; Gallbladder cancer; Gastric cancer; Gynaecological cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 17 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Jun 2010 Planned end date changed from 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 05 May 2010 Trial centres updated.